In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:
- Joint Global Coordinator in BioInvent’s in the SEK 299 million directed share issue
- Sole Global Coordinator in the SEK 200m financing consisting of a SEK 150m PIPE and a SEK 50m Fully Guaranteed Rights Issue by Abliva
- Joint Global Coordinator & Joint Bookrunner in the SEK 150 million Fully Guaranteed Rights Issue by SynAct Pharma
- Co-Manager in the USD 700 million Capital Increase by Argenx
- Sole Block Placing Agent in the placement of 1.4m Molecular Partners shares
- Joint Bookrunner in the USD 127 million Nasdaq IPO of Forbion European Acquisition Corp
- Co-Lead Manager in the USD 115 million Nasdaq Initial Public Offering by IO Biotech
- Lead manager in the USD 127 million Global Offering of Merus
- Joint Global Coordinator and Joint Bookrunner in the €31.5 million Euronext IPO by MaaT Pharma
- Co-Manager in the USD 460 million Capital Increase by Ascendis Pharma
- Joint Bookrunner in the SEK 324 million Capital Increase by Calliditas Therapeutics